Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | POLG | P54098 | 1/20 | 0.56 |
| ▸ | FAP | Q12884 | 1/20 | 0.56 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.51 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644336 | 0.93 | FGFR1 (0.73) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL20644361 | 0.88 | FGFR1 (0.79) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL173078 | 0.85 | FGFR1 (0.80) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL29258953 | 0.84 | FGFR1 (0.77) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL20644448 | 0.84 | FGFR1 (0.85) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL20644360 | 0.84 | CYP3A4 (0.73) | CYP3A4CYP2D6 | |
| SCHEMBL20644329 | 0.84 | CYP3A4 (0.73) | CYP3A4CYP2D6 | |
| SCHEMBL12875233 | 0.83 | FGFR1 (0.78) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL16063254 | 0.81 | FGFR1 (0.68) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL16063265 | 0.81 | FGFR1 (0.68) | FGFR1SLC22A6ABCB11POLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-01-18 | — | — | US | disclosed |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-20210338696-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2021-11-04 | — | — | US | disclosed |
| US-11090316-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200306272-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2020-10-01 | — | — | US | disclosed |
| US-10688112-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190015432-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | EMORY UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338696-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, GSTO1 | FGFR1 3777/4885SLC22A6 674/4885ABCB11 634/4885 |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, SGMS2 | FGFR1 3912/4885SLC22A6 669/4885ABCB11 611/4885 |
| US-10688112-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, GSTO1 | FGFR1 3777/4885SLC22A6 674/4885ABCB11 634/4885 |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, GSTO1 | FGFR1 3777/4885SLC22A6 674/4885ABCB11 634/4885 |
| US-11090316-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, SGMS2 | FGFR1 3912/4885SLC22A6 669/4885ABCB11 611/4885 |
| US-20200306272-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, SGMS2 | FGFR1 3912/4885SLC22A6 669/4885ABCB11 611/4885 |
| US-20190015432-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, GSTO1 | FGFR1 3777/4885SLC22A6 674/4885ABCB11 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.